Search

L-Glutamine

It is the principal carrier of nitrogen in the body and is an important energy source for many cells. … An oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical.

Motixafortide

two apheresis procedures, compared to ~26% of patients receiving only filgrastim. … [A261476] Motixafortide was approved by the FDA in September 2023, in combination with filgrastim, for use in stem cell mobilization prior to autologous stem cell transplant in patients with multiple

Cinnamaldehyde

It occurs naturally in the bark of cinnamon trees and other species of the genus Cinnamomum such as camphor and cassia. Sensitivity to cinnamaldehyde may be identified with a clinical patch test.

Ibalizumab

It is an advanced and current antibody in development for the treatment of HIV/AIDS. It has been developed by Taimed biologics and Theratechnologies [L1558, L1554]. … This drug was approved in March 2018 for the management of treatment-resistant HIV [L1554].

Perflubutane

Perflubutane has been used in trials studying the diagnostic of Liver Mass, Liver Diseases, Liver Metastasis, Portal Hypertension, and Peripheral Artery Disease. … It is a cardiovascular drug designed to enable ultrasound to compete more effectively with nuclear stress testing; currently the leading procedure for detecting coronary heart disease.

Vanadium

Capmatinib

involved in organ regeneration and tissue repair. … [A199122] Mutations in _MET_ have been detected in non-small cell lung cancer (NSCLC), and the prevalence of _MET_ amplification in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)

Antihemophilic factor (recombinant), PEGylated

PEGylation decreases factor VIII clearance and allowing for an increased duration of drug circulation in the plasma [L1529]. … Antihemophilic Factor (Recombinant), PEGylated, was approved by the FDA in December 2016 as the product _Adynovate_ [FDA label].